Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Headache|September 9, 2024
Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraineJessica Ailani, Pranav Gandhi, Anjana Lalla, et al.
The Journal of Clinical Endocrinology and Metabolism|May 9, 2012
Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndromeAlexander O Vortmeyer, Sven Gläsker, Gautam U Mehta, et al.
Neurology|August 3, 2018
Experimental pain assessment in patients with poststroke aphasiaChristian D Soares, Pradeep K Panuganti, Arpan Shrivastava, et al.
Neurology|August 10, 2012
Standardized sign-out improves completeness and perceived accuracy of inpatient neurology handoffsBrian D Moseley, Jonathan H Smith, Gloria E Diaz-Medina, et al.
Nature Medicine|May 12, 2025
Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trialPeter J Goadsby, Jessica Ailani, David W Dodick, et al.
Headache|July 3, 2026
Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension studyDale S Bond, Jonathan H Smith, Alexandra Sinclair, et al.
Frontiers in Human Neuroscience|October 22, 2016
Brain Changes in Responders vs. Non-Responders in Chronic Migraine: Markers of Disease ReversalCatherine S Hubbard, Lino Becerra, Jonathan H Smith, et al.
Cephalalgia : an International Journal of Headache|December 9, 2024
Weight loss with atogepant during the preventive treatment of migraine: A pooled analysisB Lee Peterlin, Dale S Bond, Jessica Ailani, et al.
Neurology|August 28, 2024
Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME TrialRichard B Lipton, Andrea M Harriott, Julia Y Ma, et al.
Neurology|June 26, 2024
Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS TrialPeter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, et al.
Pageof 8